36IN - Molecular heterogeneity in gastric cancer: Genomic approaches and clinical impact

Date 29 September 2014
Event ESMO 2014
Session Towards personalised medicine in gastric, pancreatic and liver cancer: From “omics” research to treatment
Topics Gastric Cancer
Pathology/Molecular Biology
Translational Research
Presenter Patrick Tan
Citation Annals of Oncology (2014) 25 (suppl_4): iv14-iv14. 10.1093/annonc/mdu297
Authors P. Tan
  • Cancer And Stem Cell Biology, Duke-NUS Graduate Medical School Singapore, - - Singapore/SG

Abstract

Body

Abstract:

Gastric cancer (GC) is a leading cause of global cancer mortality. Prior research has shown that GC is a molecularly heterogeneous disease, with each patient's tumor exhibiting distinct genetic and molecular profiles. However, few of these molecular differences currently impact on the clinical management of GC patients, with most patients today being treated with relatively uniform institutional protocols. In this talk, I will present and summarize recent progress from our group and others in integrating genomic and epigenomic profiles of GC patients, to identify new GC driver aberrations and discrete disease subgroups unified by common underlying molecular mechanisms. I will present evidence that the molecular heterogeneity of GC is indeed clinically relevant, impacting patient prognosis and response to therapy. Consideration of the underlying heterogeneity of GC should thus be an important factor in the evaluation of both standard and novel therapeutics in GC.

Disclosure:

The author has declared no conflicts of interest.